What To Expect At A TRT Consultation For First Timers

A TRT consultation for first-time clients follows a structured medical process: symptom review, 2 fasting morning blood draws to evaluate testosterone levels against clinical criteria, a provider evaluation, and a treatment discussion based on results. The appointment is not a quick prescription visit. It is a diagnostic workup designed to determine whether testosterone deficiency is present, identify its cause, and rule out conditions that mimic low testosterone symptoms. For men considering a direct-pay telehealth provider, knowing what each step involves removes the guesswork and sets the right expectations before that first appointment.

Testosterone replacement therapy (TRT) requires a confirmed diagnosis of hypogonadism, defined by the Endocrine Society as symptoms consistent with testosterone deficiency plus unequivocally low serum testosterone on repeated measurement (Bhasin et al., 2018). That standard shapes every step of the consultation, from initial preparation through ongoing monitoring.

How Should Patients Prepare for a TRT Consultation?

Preparation starts before the appointment date. Providers need a clear picture of the client's medical background, current medications, and symptom timeline to make accurate decisions during the evaluation.

Clients should compile a list of all current medications, including over-the-counter supplements. Opioids, glucocorticoids, and certain antiepileptic drugs can suppress testosterone production on their own, and identifying these early helps avoid misdiagnosis of primary hypogonadism when the actual cause is medication-induced (Bhasin et al., 2018). Sleep apnea history matters for the same reason, as untreated obstructive sleep apnea both lowers testosterone and is a listed contraindication for starting therapy under current guidelines.

Blood work timing is specific. Both the AUA and Endocrine Society require fasting morning samples drawn between 8 and 10 AM, when testosterone levels typically peak in the circadian cycle. Eating before the draw can lower measured testosterone enough to push a borderline value into a false-positive range. Clients should also avoid heavy exercise the day before, as acute resistance training can temporarily raise testosterone and obscure a deficiency pattern.

A symptom journal helps the consultation move faster. Providers are evaluating whether symptoms match the clinical profile of hypogonadism: reduced libido, erectile dysfunction, fatigue, loss of lean body mass, increased body fat, depressed mood, difficulty concentrating, and reduced motivation. Writing down when symptoms started, how they've progressed, and whether anything makes them better or worse gives the provider context that a single conversation might miss.

Bring questions. Clients who ask about monitoring frequency, hematocrit thresholds, fertility implications, and what happens if treatment doesn't produce expected results tend to leave the consultation with a clearer sense of what lies ahead.

The Initial Provider Evaluation

The first portion of the consultation is a clinical interview. The provider reviews the client's medical history, medication list, and symptom timeline to determine whether symptoms are consistent with testosterone deficiency or more likely explained by another condition.

This distinction matters. Fatigue, low mood, reduced energy, and weight gain overlap with thyroid disorders, depression, sleep apnea, iron deficiency, and poorly managed diabetes. A provider following AUA guidelines will evaluate these possibilities before attributing symptoms to low testosterone alone (Mulhall et al., 2018). Testosterone therapy doesn't treat the underlying condition if the root cause is something else, and starting it without ruling out reversible causes can delay the correct diagnosis.

Telehealth consultations at Marek Diagnostics follow this same evaluation framework through a video appointment. Under the current DEA temporary telemedicine flexibility, providers can prescribe Schedule III controlled substances (including testosterone) via 2-way audio-video consultation without a prior in-person visit, provided all federal and state requirements are met. This flexibility is effective through December 31, 2026, and permanent rules remain under development. State licensure and clinical standards still apply, and the prescription requires a legitimate medical purpose and standard diagnostic confirmation.

The provider will also ask about fertility goals. Current Endocrine Society and AUA guidelines recommend against prescribing testosterone to men planning to conceive in the near term. Exogenous testosterone commonly suppresses spermatogenesis, and while suppression is not guaranteed to be permanent in every case, the risk warrants a conversation before treatment starts, not after.

What Happens During the Medical Evaluation?

The medical evaluation centers on blood work. A diagnosis of hypogonadism requires 2 separate early-morning total testosterone measurements, drawn 1-3 weeks apart, using the same lab and assay method each time (Mulhall et al., 2018). A single low value is not sufficient. Testosterone fluctuates day to day, and a second confirmatory draw reduces the chance of diagnosing a transient dip as a chronic deficiency.

The AUA and other endocrine societies define diagnostic thresholds that vary by assay method and clinical context (AUA: Moderate Recommendation). Levels alone don't establish a diagnosis. The client must also have symptoms or signs of deficiency, and the treating provider interprets results against the appropriate guideline cutoff for the assay used.

A standard pre-treatment lab panel typically includes:

• Total testosterone (2 separate fasting morning draws, 8-10 AM)

• Free testosterone or calculated free testosterone when total testosterone is near the diagnostic threshold

• SHBG (sex hormone-binding globulin), tested when obesity, thyroid disease, or aging may alter binding protein levels

• LH (luteinizing hormone) and FSH to distinguish primary hypogonadism (testicular failure) from secondary hypogonadism (pituitary or hypothalamic origin)

• Hematocrit and hemoglobin (baseline, since testosterone can raise red blood cell production)

• PSA (prostate-specific antigen) as indicated by age and risk factors

• Metabolic markers, lipid panel, and liver function tests

The distinction between total and free testosterone is clinically meaningful but often overlooked. The Endocrine Society recommends measuring free testosterone by equilibrium dialysis or a validated calculation when total testosterone falls near the lower limit or when SHBG is likely altered. Relying on total testosterone alone can misclassify clients in both directions: a man with high SHBG may have low free testosterone despite a "normal" total, and a man with low SHBG may have adequate free testosterone despite a total that looks deficient.

Providers also evaluate whether the low testosterone has a reversible cause. Obesity is among the most common causes of secondary hypogonadism, and weight loss alone may raise testosterone levels without pharmacologic intervention. Medications, chronic illness, and pituitary disorders are other treatable causes that a thorough lab evaluation can identify.

TRT Delivery Methods and Formulations

If blood work confirms a testosterone deficiency and the provider determines that TRT is medically appropriate, the consultation moves to treatment options. Several testosterone formulations are available, each with distinct dosing schedules, pharmacokinetics, and practical considerations.

Intramuscular injections (testosterone cypionate and enanthate) are the most commonly prescribed formulations in the U.S. Dosing is typically weekly or every 1-2 weeks by intramuscular or subcutaneous injection. These formulations produce a peak-trough pattern, with higher levels in the days after injection and lower levels before the next dose. Monitoring is usually done at the midpoint between injections. Both cypionate and enanthate are available as FDA-approved branded products and as compounded preparations. Compounded testosterone is not FDA-approved and is prepared under 503A (patient-specific) or 503B (outsourcing facility) pharmacy rules.

Transdermal gels provide a daily application that maintains steadier testosterone levels without the peak-trough pattern of injections. A key safety consideration is secondary exposure: testosterone gel can transfer to others through skin contact, which is a meaningful concern for clients with partners or children in the household.

Pellets are surgically implanted subcutaneously every 3-6 months. They provide a long-duration delivery option but require a minor in-office procedure for insertion and are not easily adjustable if dosing needs to change. Marek Diagnostics does not offer this formulation.

Oral testosterone undecanoate is an FDA-approved formulation taken twice daily with food. Unlike older oral testosterone products that carried hepatotoxicity risk, undecanoate is absorbed through the lymphatic system and bypasses first-pass liver metabolism. The February 2025 FDA labeling update added blood-pressure monitoring recommendations for all testosterone products, and this is especially relevant for oral formulations given the pharmacokinetic profile.

The choice depends on the client's preference, lifestyle, and medical profile. The provider should explain each option's dosing schedule, administration method, and monitoring requirements during the consultation so the client can make an informed decision.

Response Timeline and What to Expect

Clients starting TRT commonly ask how long before they notice changes. The answer depends on the symptom, and published data provides general ranges rather than guaranteed timelines.

Libido and sexual interest may improve within 3-6 weeks for some clients with confirmed deficiency. Energy and mood changes are more variable and may take 6-12 weeks to become noticeable. Body composition shifts, such as reductions in fat mass and increases in lean mass, are among the slowest to appear and often require 3-6 months of consistent treatment combined with adequate nutrition and resistance training.

These timelines are not guarantees. Response varies by individual, formulation, dosing, and the severity of the deficiency. The Endocrine Society recommends evaluating response at 3-6 months and adjusting the treatment plan based on symptom improvement, lab values, and the presence of adverse effects. Clients with unrealistic short-term expectations may discontinue before the therapy has had time to take effect. The consultation is the right time for the provider to set those expectations.

If a client does not respond to initial dosing, the evaluation may need to revisit whether the diagnosis is correct, whether the formulation or dose needs adjustment, or whether an unrecognized contributing factor (sleep apnea, obesity, medication effects) is limiting the response.

Direct-Pay Pricing and What Costs Include

TRT through a direct-pay telehealth provider operates outside traditional insurance billing. This model has specific cost implications that clients should understand before starting.

A TRT consultation at Marek Diagnostics uses a direct-pay model. Clients should ask during the initial consultation what the total cost includes and what it does not. Key questions: Does the consultation fee include lab work, or are labs billed separately? What is the cost of the medication itself, and does it vary by formulation? Are follow-up appointments included in the initial fee, or billed per visit? Is there a subscription or membership component, and if so, what are the cancellation terms?

Direct-pay. HSA/FSA may be eligible.

Asking these questions upfront prevents billing surprises after treatment begins. A telehealth provider should be willing to disclose its full fee structure before the client commits to treatment. If a provider avoids pricing questions or buries costs behind an initial consultation fee, that is worth noting.

What Does Ongoing Monitoring Look Like?

Monitoring is not optional. It is a required component of responsible TRT management, and the consultation should include a clear explanation of what monitoring involves and how often it occurs.

The Endocrine Society recommends evaluating testosterone levels, symptoms, and adverse effects at 3-6 months after starting therapy, then annually once stable (Bhasin et al., 2018). The AUA adds that hematocrit and hemoglobin should be checked at baseline, at 3-6 months, and periodically after that.

Hematocrit monitoring deserves specific attention. Testosterone stimulates erythropoiesis (red blood cell production), and a rising hematocrit is the most common lab-detectable adverse effect of TRT. If hematocrit rises above guideline-recommended thresholds, providers typically pause therapy until values fall to a safe level, evaluate for contributing causes such as hypoxia or obstructive sleep apnea, and consider restarting at a lower dose if appropriate. Clients who skip monitoring can develop erythrocytosis without knowing it, which raises the risk of thromboembolic events.

PSA screening is recommended based on age and risk factors before starting TRT and during follow-up. Current evidence does not establish a causal link between testosterone therapy and prostate cancer in men without active disease, but TRT is contraindicated in men with active prostate or breast cancer, and a rising PSA on therapy warrants further evaluation.

The TRAVERSE trial (Lincoff et al., 2023) provided the largest cardiovascular safety dataset to date: 5,246 men with hypogonadism and preexisting or high cardiovascular risk, followed for a mean of 33 months. The primary cardiac endpoint (cardiovascular death, nonfatal MI, or nonfatal stroke) was noninferior in the testosterone group (7.0% vs 7.3%, HR 0.96). However, the testosterone group had higher rates of atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%), and pulmonary embolism (0.9% vs 0.5%). These secondary findings are part of the complete safety picture and should be discussed during the monitoring plan portion of the consultation.

Following the TRAVERSE results, the FDA issued class-wide labeling changes for testosterone products in February 2025. The update added TRAVERSE data to labels, removed language from the Boxed Warning related to increased risk of adverse cardiovascular outcomes, retained the "Limitation of Use" for age-related testosterone decline, and added a blood-pressure warning.

Monitoring appointments also assess symptom response. Lab values matter, but the treatment target is mid-normal testosterone concentrations with symptom improvement and absence of serious adverse effects. A client whose labs look ideal but whose symptoms haven't improved needs a different conversation than a client with improving symptoms and stable labs.

Patient Resources After the First Appointment

The consultation is the beginning of an ongoing provider-client relationship, not a single transaction. Clients should leave the appointment knowing their follow-up schedule, the expected timeline for lab rechecks, and whom to contact if symptoms worsen or side effects develop between appointments.

A TRT monitoring schedule typically follows this cadence: first follow-up blood work at 6-12 weeks to assess early response and check hematocrit, then a more thorough review at 3-6 months including testosterone levels, symptom evaluation, and a full safety panel. Once the client is stable on a consistent dose, annual monitoring is standard.

Clients should also ask about what happens if they want to stop therapy. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, and discontinuation without a plan can result in a period of below-baseline testosterone levels until endogenous production recovers (which is not guaranteed to return to pre-treatment levels). The Endocrine Society recommends discussing this possibility before starting therapy, not after the client decides to stop.

Lifestyle factors remain relevant during TRT. Sleep quality, resistance training, body composition management, and alcohol use all influence testosterone metabolism and treatment response. A provider who addresses these factors alongside pharmacologic therapy gives the client a more complete framework for long-term success.

Clients evaluating which biomarkers to test during ongoing monitoring can ask for a clear breakdown of what each marker measures, why it matters, and what thresholds trigger a dosing change. That level of transparency is a reasonable expectation from any provider managing a Schedule III controlled substance.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Do patients need 2 separate blood draws before a provider can prescribe testosterone?

Yes. Both the Endocrine Society and the AUA require at least 2 early-morning total testosterone measurements, drawn 1-3 weeks apart, plus symptoms or signs of deficiency before diagnosing hypogonadism. A single low value is not sufficient because testosterone levels fluctuate from day to day. This 2-draw requirement protects against treating a temporary dip as a chronic condition.

What happens if hematocrit rises above safe levels during TRT?

The Endocrine Society recommends checking hematocrit at baseline, at 3-6 months, and periodically after that. If hematocrit rises above guideline-recommended thresholds, the provider typically pauses testosterone until values drop to a safe level, evaluates for contributing causes such as obstructive sleep apnea or hypoxia, and considers restarting at a reduced dose if medically appropriate. Skipping this monitoring is the most common safety gap in TRT management.

Can a telehealth provider prescribe testosterone without an in-person visit?

Under the current DEA and HHS temporary telemedicine flexibility, a registered practitioner can prescribe Schedule III testosterone via 2-way audio-video consultation without a prior in-person visit, provided all federal and state requirements are met. This flexibility is effective through December 31, 2026. Permanent rules are pending, and state-level telemedicine and pharmacy laws vary. Access remains conditional, not guaranteed.

Does the TRAVERSE trial mean testosterone carries no cardiovascular risk?

No. TRAVERSE showed that the primary cardiac endpoint (cardiovascular death, nonfatal MI, or nonfatal stroke) was noninferior in the testosterone group compared to placebo (7.0% vs 7.3%). However, the testosterone group had higher rates of atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%), and pulmonary embolism (0.9% vs 0.5%). The FDA removed specific Boxed Warning language on major adverse cardiac events but added a blood-pressure warning in its February 2025 labeling update.

Will TRT permanently stop sperm production?

Exogenous testosterone commonly suppresses spermatogenesis, but the effect is variable. It is not guaranteed to be permanent or complete in every individual. Both the AUA and the Endocrine Society recommend against starting TRT in men planning to conceive in the near term. Clients with fertility goals should discuss alternatives such as hCG or selective estrogen-receptor modulators with their provider before starting testosterone.

Why do different labs report different "normal" testosterone ranges?

Assay methods and reference populations differ across laboratories. A sample measured at 1 lab may read as low-normal, while the same sample at another reads within range. The Endocrine Society recommends using accurate, preferably CDC-standardized assays and interpreting results in the clinical context rather than relying on a single lab's printed reference range. This is part of the reason guidelines require 2 confirmatory draws using the same assay.

What questions should patients ask about an exit plan if they stop TRT?

Clients should ask their provider about the expected recovery timeline for endogenous testosterone production after discontinuation, whether a taper protocol will be used, and whether adjunctive medications (such as hCG or clomiphene) may support recovery. They should also ask whether the provider has a defined monitoring schedule for the post-discontinuation period. Endogenous testosterone production does not always return to pre-treatment levels, and having a plan in place before starting therapy is better than improvising after the fact.

References

• Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.

• Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432.

• Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389:107-117.

• FDA Issues Class-Wide Labeling Changes for Testosterone Products. FDA Drug Safety Communication. February 28, 2025.

• Testosterone Information. FDA Postmarket Drug Safety Information. Updated 2025.